NeoGenomics, Inc. Revised Earnings Guidance for Full-Year 2021. For the period, the company expects consolidated revenue to be in the range of $482.5 million to $487.5 million as compared to initial guidance of $490 million to $510 million and net loss to be in the range of $0.8 million to $4.2 million as compared to initial guidance of $70 million to $65 million.